No Data
No Data
DSS Unit Impact Biomedical Sets Terms for Downsized $6M IPO
DSS Unit Impact BioMedical Reduces Planned IPO Size to 1.5M Shrs From 2M, Still Expects Price Between $3 and $5 Each
DSS Unit Impact BioMedical Reduces Planned IPO Size to 1.5M Shrs From 2M, Still Expects Price Between $3 and $5 Each
DSS Inc | 10-Q: Quarterly report
DSS and PRPL Among Consumer Discretionary Movers
Express News | Impact Biomedical Announces U.S. Patent Allowance Of Laetose Technology Titled "Low Glycemic Sugar Composition"
Impact Biomedical, Inc. Announces U.S. Patent Allowance of Laetose Technology Entitled "Low Glycemic Sugar Composition."
NEW YORK, Jan. 30, 2024 (GLOBE NEWSWIRE) -- Impact Biomedical Inc. (IBIO), in which DSS Inc.(NYSE:DSS) has a significant investment, is thrilled to announce a milestone in its innovative Laetose technology
No Data